Last update 17 May 2025

Interferon-alpha gene therapy(Amarillo Biosciences, Inc.)

Overview

Basic Info

Drug Type
Gene therapy
Synonyms-
Target
IFN α
Action
agonists
Mechanism
IFN α agonists(interferon alpha agonists)
Therapeutic Areas
NeoplasmsDigestive System DisordersImmune System Diseases+ [2]
Active Indication-
Inactive Indication
Head and Neck NeoplasmsHemangioendotheliomaHepatocellular Carcinoma+ [1]
Originator Organization
Amarillo Biosciences, Inc.Amarillo Biosciences, Inc.
Active Organization-
Inactive Organization
F. Hoffmann-La Roche Ltd.The Johns Hopkins UniversityThe Johns Hopkins UniversityAmarillo Biosciences, Inc.Amarillo Biosciences, Inc.
License Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Interferon-alpha gene therapy(Amarillo Biosciences, Inc.)
NCT00690885
/ TerminatedPhase 2
Evaluation of Natural Human Interferon Alpha Lozenges in the Treatment of Chronic Cough in Patients With Chronic Obstructive Pulmonary Disease (COPD) or Idiopathic Pulmonary Fibrosis (IPF)
100 Clinical Results associated with Interferon-alpha gene therapy(Amarillo Biosciences, Inc.)
Login to view more data
100 Translational Medicine associated with Interferon-alpha gene therapy(Amarillo Biosciences, Inc.)
Login to view more data
100 Patents (Medical) associated with Interferon-alpha gene therapy(Amarillo Biosciences, Inc.)
Login to view more data
100 Deals associated with Interferon-alpha gene therapy(Amarillo Biosciences, Inc.)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatocellular CarcinomaPhase 3-
F. Hoffmann-La Roche Ltd.
-
Hepatocellular CarcinomaPhase 3-
The Johns Hopkins UniversityThe Johns Hopkins University
-
Head and Neck NeoplasmsPhase 2-
The Johns Hopkins UniversityThe Johns Hopkins University
-
Head and Neck NeoplasmsPhase 2-
F. Hoffmann-La Roche Ltd.
-
HemangioendotheliomaPhase 2-
The Johns Hopkins UniversityThe Johns Hopkins University
-
HemangioendotheliomaPhase 2-
F. Hoffmann-La Roche Ltd.
-
HIV InfectionsPreclinical-
F. Hoffmann-La Roche Ltd.
-
HIV InfectionsPreclinical-
The Johns Hopkins UniversityThe Johns Hopkins University
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free